- Molecular NameRifabutin
- SynonymAnsatipin; Ansatipine; Antibiotic LM 427; RBT; Rifabutina [Spanish]; Rifabutine [French]; Rifabutinum [Latin]
- Weight849.035
- Drugbank_IDDB00615
- ACS_NO72559-06-9
- Show 3D model
- LogP (experiment)4.5
- LogP (predicted, AB/LogP v2.0)4.15
- pka3.5; 6.5; 9.5
- LogD (pH=7, predicted)1.32
- Solubility (experiment)0.19 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-6.59
- LogSw (predicted, AB/LogsW2.0)0.17
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors5
- No.of HBond Acceptors15
- No.of Rotatable Bonds5
- TPSA205.55
- StatusFDA approved
- AdministrationN/A
- PharmacologyA bactericidal antibiotic drug primarily used in the treatment of tuberculosis.
- Absorption_valueN/A
- Absorption (description)Rifabutin is readily absorbed from the gastrointestinal tract, with an absolute bioavailability averaging 20%.
- Caco_2N/A
- Bioavailability20.0
- Protein binding80.0
- Volume of distribution (VD)8~9 L/kg (in HIV-infected patients)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Of the five metabolites that have been identified, 25-O-desacetyl and 31-hydroxy are the most predominant. The former metabolite has an activity equal to the parent drug and contributes up to 10% to the total antimicrobial activity.
- Half life45 h
- ExcretionRenal and fecal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)LD50=4.8 g/kg